Redeye updates on Better Collective ahead of Q4-results (due 21 May after market close) where focus ...
Redeye provides its initial take on Surgical Science’s Q1 2025 report, which mostly beat our estimat...
Redeye updates its estimates and fair value range following CoinShares' Q1 2025 report.
Redeye returns with an updated view following Nekkar’s Q1 figures that was surprisingly soft even if...
Relais' Q1 results were well in line with LSEG Data and Analytics consensus expectations, while the ...
Strong momentum in GC&MP, headwinds in NW&FT and FW '25e-'27e sales CAGR of +14% New product launche...
Expect continued M&A, mainly in DACH 5% adj. EBITA CAGR '24-'27e, M&A to support 10% growth 10-7x EB...
CEO Daniel Krook emphasised the increased growth focus for H1.
EcoRub (”EcoRub” eller ”bolaget”) publicerade den 12 maj 2025 bolagets delårsrapport för det första ...
EQL Pharma presterar starkt och visar upp en väl tilltagen omsättningstillväxt i kombination med god...
VibroSense redovisade en nettoomsättning om 0,75 MSEK (0,47) i kvartalet, vilket var en ökning med 5...
BIovica has entered a reference lab agreement with Tempus a US listed company.
Redeye has interviewed Pia Renaudin, CEO at Scibase, in connection with the Q1 report.
Den 12 maj 2025 meddelade AcuCort (”AcuCort” eller ”Bolaget”) att Bolaget mottagit en ny order på Ze...
ByggPartnerGruppen levererade en stark rapport där orderingången närapå dubblades.
Redeye comments on IRLAB’s announcement of extended U.
Redeye states CoinShares surpassed its EBITDA expectations by 14%, primarily due to the CSCM segment...
Relais reported Q1 adjusted EBITA of EUR 9.2m was down 5% y/y, in line with LSEG Data & Analytics co...
Net sales of SEK67.7m were almost SEK9m higher than expected.
Redeye has updated its near-term estimates and valuation following the Q1 report.